Supplementary Information

Development of Cationic Lipid-Conjugated Haloperidol Derivatives as Sigma Receptor Targeted Anticancer Therapeutics

Krishnendu Pal, Subrata Kumar Pore, Sutapa Sinha, Rajiv Janardhanan, Debabrata Mukhopadhyay, Rajkumar Banerjee

Figure S1









Figure S1: Viability studies of B16F10 cells continuously treated with a range of concentrations of haloperidol (\triangle), C8-molecule (\circ), HP + C8 (\blacklozenge), and HP-C8 (\square) respectively for 48 hours. *** denotes p<0.001.
























HPLC Diagrams of Synthesized Derivatives











S11











HPLC Conditions:

System : Varian ProStar HPLC

Column : Varian microsorb 100-10 BDS column (4.6 mm×250 mm)

Mobile Phase : A- Methanol

B- Methanol: Water (95:5)

Flow Rate : 1ml/min

Column Pressure : 55-60Kg/cm²

Temperature : 25^oC

Wavelength : 210nm